Higano CS - Search Results

1

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Smith MR, et al. Among authors: higano cs. Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6. Eur Urol. 2016. PMID: 27160947 Free PMC article. Clinical Trial.

2

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Higano CS. Higano CS. Urology. 2003 Feb;61(2 Suppl 1):32-8. doi: 10.1016/s0090-4295(02)02397-x. Urology. 2003. PMID: 12667885 Review.

3

The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.

Cherrier MM, Rose AL, Higano C. Cherrier MM, et al. J Urol. 2003 Nov;170(5):1808-11. doi: 10.1097/01.ju.0000091640.59812.83. J Urol. 2003. PMID: 14532781 Clinical Trial.

4

Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.

Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Carroll PR, et al. Among authors: higano cs. J Urol. 2003 Dec;170(6 Pt 2):S3-5. doi: 10.1097/01.ju.0000095101.18470.a0. J Urol. 2003. PMID: 14610403 Review. No abstract available.

5

Management of bone loss in men with prostate cancer.

Higano CS. Higano CS. J Urol. 2003 Dec;170(6 Pt 2):S59-63; discussion S64. doi: 10.1097/01.ju.0000097351.48848.1f. J Urol. 2003. PMID: 14610412 Review.

6

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.

Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS. Beer TM, et al. Among authors: higano cs. Clin Cancer Res. 2004 Feb 15;10(4):1306-11. doi: 10.1158/1078-0432.ccr-1021-03. Clin Cancer Res. 2004. PMID: 14977829 Clinical Trial.

7

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Diamond TH, et al. Among authors: higano cs. Cancer. 2004 Mar 1;100(5):892-9. doi: 10.1002/cncr.20056. Cancer. 2004. PMID: 14983482 Free article. Review.

8

Metastases of prostate cancer express estrogen receptor-beta.

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Lai JS, et al. Among authors: higano cs. Urology. 2004 Oct;64(4):814-20. doi: 10.1016/j.urology.2004.05.036. Urology. 2004. PMID: 15491740

9

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Smith MR, et al. Among authors: higano cs. J Clin Oncol. 2005 May 1;23(13):2918-25. doi: 10.1200/JCO.2005.01.529. J Clin Oncol. 2005. PMID: 15860850 Clinical Trial.

10

Current status of treatment for patients with metastatic prostate cancer.

Higano CS. Higano CS. Can J Urol. 2005 Jun;12 Suppl 2:38-41. Can J Urol. 2005. PMID: 16018832 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters